In addition, management of XTL effectively improved blood glucose control in 66.7% of diabetic patients (n  =  24) with secondary failure of sulfanylurea [104]; XTL treatment also increased insulin sensitivity index in T2DM patients (n  =  47) compared with glibenclamide (n  =  35), which indicated that treatment of XTL could improve insulin resistance in T2DM patients. This evidence concerns the gene INS and Insulin resistance.